Prognostic value of metabolic tumour volume and total lesion glycolysis measured by 18F‐fluorodeoxyglucose positron emission tomography/computed tomography in small cell lung cancer: A systematic review and meta‐analysis

Summary The aim of this study was to evaluate the prognostic value of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) for small cell lung cancer (SCLC). MEDLINE, EMBASE and Cochrane Library databases were systematically searched. The pooled hazard ratio (HR) was used to measure the influence of MTV and TLG on survival. The subgroup analysis according to VALSG stage and the measured extent of MTV was performed. Patients with high MTV values experienced a significantly poorer prognosis with a HR of 2.42 (95% CI 1.46–4.03) for overall survival (OS) and a HR of 2.78 (95% CI 1.39–5.53) for progression‐free survival (PFS) from the random effect model, and the pooled HR from the fixed effect model was 2.10 (95% CI 1.77–2.50) for OS and 2.27 (95% CI 1.83–2.81) for PFS. Patients with high TLG experienced a poorer prognosis with a HR of 1.61 (95% CI: 1.24–2.07) for OS from the random effect model, and the pooled HR from the fixed effect model was 1.64 (95% CI 1.37–1.96). Heterogeneity among studies was high for MTV in both OS and PFS meta‐analyses (I2 = 87% and 88% respectively). After removing one outlier study the heterogeneity was substantially reduced (I2 = 0%) and the pooled HR for the effect of MTV on OS was 1.80 (1.51–2.16, P